ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Allena Pharmaceuticals Inc

Allena Pharmaceuticals Inc (ALNA)

0.075
0.00
(0.00%)
Closed November 03 4:00PM
0.00
0.00
(0.00%)

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
0.075
Bid
0.0825
Ask
0.0832
Volume
-
0.00 Day's Range 0.00
0.00 52 Week Range 0.00
Previous Close
0.075
Open
-
Last Trade
Last Trade Time
Average Volume (3m)
-
Financial Volume
-
VWAP
-

ALNA Latest News

Allena Pharmaceuticals Announces New Meeting Date and New Record Date for Special Meeting to Approve Reverse Stock Split

NEWTON, Mass., July 12, 2022 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class...

Allena Pharmaceuticals Announces Rescheduling of Special Meeting to Approve Reverse Stock Split

NEWTON, Mass., July 05, 2022 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class...

Allena Pharmaceuticals Gets Fast Track Designation for Kidney Disease Treatment

By Chris Wack Allena Pharmaceuticals Inc. said its orally-administered, urate-degrading enzyme, ALLN-346, has received Fast Track designation from the U.S. Food and Drug Administration. ALLN-346...

Allena Pharmaceuticals to Host Key Opinion Leader Webinar Focused on ALLN-346 for the Treatment of Gout in Patients with Chro...

NEWTON, Mass., June 08, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals (NASDAQ: ALNA), a late-stage biopharmaceutical company dedicated to discovering, developing and commercializing...

Allena Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update

-- Enrollment ongoing in Phase 3 URIROX-2 clinical trial of reloxaliase; interim analysis expected 2Q or 3Q 2022 Enrolling healthy volunteers in Phase 1b MAD study of ALLN-346; initial data...

Allena Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

NEWTON, Mass., May 04, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage biopharmaceutical company dedicated to discovering, developing and commercializing...

Allena Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

NEWTON, Mass., April 08, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage biopharmaceutical company dedicated to discovering, developing and commercializing...

Allena Pharmaceuticals Appoints Mark J. Fitzpatrick to its Board of Directors

NEWTON, Mass., April 07, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage biopharmaceutical company dedicated to developing and commercializing first-in-class...

Allena Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update

    -- Reloxaliase continues to progress through ongoing pivotal Phase 3 URIROX-2 trial for enteric hyperoxaluria -- -- ALLN-346 poised to enter Phase 1 multiple-ascending dose and Phase 2a trials...

Allena Pharmaceuticals to Present at Upcoming Investor Conferences in March

NEWTON, Mass., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage biopharmaceutical company dedicated to developing and commercializing first-in-class...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000CS
40000000CS
120000000CS
260000000CS
520000000CS
1560000000CS
2600000000CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
VSTEVast Renewable Ltd
$ 4.98
(149.00%)
68.54M
INVZWInnoviz Technologies Ltd
$ 0.096
(96.71%)
22.71k
CDXCChromaDex Corporation
$ 5.87
(68.19%)
37.88M
ATHAAthira Pharma Inc
$ 0.606
(41.56%)
239.63M
TILEInterface Inc
$ 23.24
(33.03%)
2.16M
EPIXESSA Pharma Inc
$ 1.45
(-72.12%)
34.3M
ELABElevai Labs Inc
$ 0.0288
(-51.19%)
202.28M
OSTOstin Technology Group Company Ltd
$ 0.275
(-45.00%)
2.27M
LXRXLexicon Pharmaceuticals Inc
$ 1.23
(-36.92%)
21M
VCIGVCI Global Ltd
$ 0.0583
(-27.58%)
26.57M
ATHAAthira Pharma Inc
$ 0.606
(41.56%)
239.63M
SQQQProShares UltraPro Short QQQ
$ 7.44
(-2.11%)
216.16M
NVDANVIDIA Corporation
$ 135.40
(1.99%)
209.27M
ELABElevai Labs Inc
$ 0.0288
(-51.19%)
202.28M
INTCIntel Corporation
$ 23.20
(7.81%)
173.47M

Discussion

View Full Feed
zab zab 4 minutes ago
Trump just like his supporters always want to make America a nasty place, they enjoy making anything disgusting like Trump did with his microphone yesterday. I still enjoy Steve Jobs and how Apple transformed everyone with a smart phone. Now that's real change in America.
rmmc rmmc 6 minutes ago
Investing is not a sure thing for anyone, especially on OTC stocks such as HIRU. But the returns are great if you do not fall in love with a stock. But why do bashers assume everyone that buys the stock is gullible. "Investors here are so gullible." Many here play the OTC board for what it is
HIRU
oldstocks oldstocks 7 minutes ago
Dell Technologies has been involved in several smart city projects in Saudi Arabia, including:
King Abdullah Financial District Project
Dell Technologies partnered with Orange Business Services to participate in the signing ceremony for this multi-million dollar smart city project in S
AFFU
gfp927z gfp927z 7 minutes ago
Silver_bars, Thanks for the insights :o)

I figure one aspect with a Trump victory is a jump in inflation due to the big tarrif increases, so that could boost gold. On the other hand, the Fed may have to keep % rates higher, which could work against higher gold prices. But who kn
Investor2014 Investor2014 8 minutes ago
You should read the link you posted again.
The confirmatory Phase 3 TRAILBLAZER-ALZ 2 trial remains ongoing, with topline data read-out expected in Q2 2023, and will form the basis of donanemab's application for traditional approval shortly thereafter. Lilly will continue to work with the FDA
AVXL
Trinityz1 Trinityz1 8 minutes ago
Pretty good stuff....
I saw it....but nice she's called out on it
stockinspector stockinspector 8 minutes ago
Ken's appointment calender I would surmise. When we get past this election and open the free market
and allow small companies to flourish as the majority of the world knows it should.
WDLF
ANTI-BAGHOLDER ANTI-BAGHOLDER 9 minutes ago
Big update on MONI this weekend.  Things are starting to move fast now. 

 https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175325885
MONI
zab zab 9 minutes ago
Fort Ticonderoga is the Northern End, Fort William Henry is the southern end. It's a beautiful lake, and 40 years after I left its still beautiful.
CaptBeer CaptBeer 10 minutes ago
$AMRN Part IV: Q&A Session with several good questions about IPE begins at 3:08:18
Are the effects of IPE independent of TG reduction?
Should you use IPE in patients with “normal” TG’s
What about the concern for AFib?


https://investorshub.advfn.com/uimage/
AMRN
Bubae Bubae 10 minutes ago
I doubt GS Capital dumped the shares issued in Q1 while CEO Joe was running his infomercials. It is more likely that he was supporting the conversions that would be working through their rule 144 180 day holding period. These toxic lenders have been getting hammered by the SEC for these notes and d
BEGI
BullNBear52 BullNBear52 11 minutes ago
Thank goodness for Mrs. Smith. 9 1/2 hours to bake a pie.

Dutch Apple Pie
By Cybelle Tondu
Published Oct. 29, 2024

https://investorshub.advfn.com/uimage/uploads/2024/11/3/awhokCT-Dutch-Apple-Pierex-mqgw-jumbo-v2.webp

Dutch Apple Pie
CaptBeer CaptBeer 11 minutes ago
$AMRN Part III: Management of Hypertriglyceridemia:

In patients with well controlled LDL-c on statin therapy with TG’s 135-499 mg/dl the addition of IPE is recommended as a proven benefit to lower CVE’s (MACE).

https://investorshub.advfn.com/uimage/uploads/2024/11/3/dw
AMRN
flipper44 flipper44 12 minutes ago
Thank you for reminding/highlighting that section from Dr. Bosch’s speech linked in post 729944.

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175325520
NWBO
KVM KVM 12 minutes ago
Could be most of guidance shortfall related to Veri Hire. Looks like a major slowdown in hiring post pandemic is finally catching up to the industry. Doesn't bode well.
VERI
CaptBeer CaptBeer 12 minutes ago
$AMRN Part II: REDUCE-IT EPA Mediation Analysis:

Even though REDUCE-IT was based on the premise that TG lowering without raising LDL-c is major pathway to CVD RR, it’s beginning to be seen that TG lowering may play a minor role in the MOA for CVD Risk Reduction. The REDUCE-IT Mediati
AMRN
Donotunderstand Donotunderstand 12 minutes ago
are you saying - indirectly - that cost per truck - (loss of 350K) - will not go down when NKLA is producing say 1,500 trucks a year ?

Anyone have any slides or ? as to what management may have said or shown in last 12-18 months about how volume impacts cost per truck produced at ove
NKLA
CashCowMoo CashCowMoo 13 minutes ago
London bridge is falling down falling down falling down 
DBMM
Whalatane Whalatane 13 minutes ago
20 degrees C is 68 degrees F ....So how long is that $74 M in long term inventory good for ? And when does normal inventory become long term inventory ?

Kiwi
AMRN
fung_derf fung_derf 13 minutes ago
It's funny that some posters immediately come to deerballs defense rather than asking why in heck deerballs name would even come up in the company's legal battles.
Shouldn't you all be more concerned that perhaps a poster here who has been feeding you news for years, may be complicit?
VPLM
SusieQutie SusieQutie 13 minutes ago
Are you insane?!? Do they own $RONN retail shares?!? They’re not the fools. They sell those shares to gullible stinky pinky investors and use the $$$ for their lavish lifestyles that you don’t have lol.
RONN
CaptBeer CaptBeer 13 minutes ago
$AMRN Part 1: Most of you know that Dr. Bhatt has moved from Boston’s Brigham & Women’s Hospital to the Mount Sinai Fuster Heart Hospital in NYC. Today there was a live broadcast with CME Course Credit moderated by Dr. Bhatt titled: Top-10 Topics in clinical cardiology from Mount Sinai with experts
AMRN CME
mzasif mzasif 14 minutes ago
Hope the 10Q is out soon..showing profits as they always except last Q.
Or otherwise this will go to EM status if filing not out in time.
UNQL
Brokemillwright Brokemillwright 15 minutes ago
2 years ago, now your shilling again lol

Meanwhile the CE is still on as I SAID and the stock price is at or below the .0003
Price range....



This company is burnt toast like its owner, LOL


RSI38
NPHC